Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee

Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. doi: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29.


The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation (ASBMT) sought to develop an evidence-based review about personalizing busulfan-based conditioning. The Committee sought to grade the relevant published studies (June 1, 2008 through March 31, 2016) according to criteria set forth by the Steering Committee for Evidence Based Reviews from ASBMT. Unfortunately, the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible. Despite this observation, the continued interest in this topic led the Practice Guidelines Committee to develop a list of most frequently asked questions (FAQs) regarding personalized busulfan dosing. This "Considerations" document is a list of these FAQs and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians.

Keywords: Busulfan; Hematopoietic cell transplantation; Pharmacokinetics; Precision medicine; Therapeutic drug monitoring.

Publication types

  • Practice Guideline
  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Busulfan / administration & dosage*
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Myeloablative Agonists / therapeutic use
  • Precision Medicine / methods*
  • Transplantation Conditioning / methods*


  • Myeloablative Agonists
  • Busulfan